MedPath

Trial of alpha-interferon in chronic myeloid leukaemia and a comparison of busulphan and hydroxyurea for induction and maintenance

Not Applicable
Completed
Conditions
eukaemia (chronic)
Cancer
Registration Number
ISRCTN46123985
Lead Sponsor
Medical Research Council (MRC) (UK)
Brief Summary

1995 results in: https://www.ncbi.nlm.nih.gov/pubmed/7760609 (added 15/11/2019)

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
587
Inclusion Criteria

1. Aged over 75 years with either Ph positive or Ph negative chronic myeloid leukaemia in chronic phase. Patients over 75 years or patients unwilling to accept alpha-interferon, may be randomised to busulphan or hydroxyurea, but not interferon or no interferon
2. Adequate renal function
3. No severe concurrent hepatic, renal, cardiovascular, organic brain disease or psychiatric illness
4. Patients with established blast cell crisis or extramedullary granulocytic sarcomas are to be excluded
5. Patients with accelerated phase or platelet count below that specified in the protocol are not eligible

Exclusion Criteria

Not provided at time of registration.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
ot provided at time of registration.
Secondary Outcome Measures
NameTimeMethod
ot provided at time of registration.
© Copyright 2025. All Rights Reserved by MedPath